Exploring the EMERALD Trial: What the Subgroup Analyses of Advanced Breast Cancer Patients Found

Exploring the EMERALD Trial: What the Subgroup Analyses of Advanced Breast Cancer Patients Found 

Exploring the EMERALD Trial: What the Subgroup Analyses of Advanced Breast Cancer Patients Found
RestartResume

    Join us as take a deep dive into a recent study investigating the use of an oral SERD for the treatment of advanced breast cancer.

    • Overview

      For patients with ER+/HER2- advanced breast cancer, current treatment guidelines recommend the use of endocrine therapy plus a CDK 4/6 inhibitor as a first-line treatment. And while the guidelines recommend sequential endocrine therapy for disease progressions, this progression can lead to ESR1 mutations and resistance to endocrine therapy. Could a novel oral selective estrogen receptor have more efficacy in preventing ESR1 mutations associated with endocrine resistance? That’s the exact question the EMERALD trial sought to answer, and what this study found in its subgroup analyses is the focus of this Audio Abstract.

    Facebook Comments

    Register

    We’re glad to see you’re enjoying Global Women's Health Academy…
    but how about a more personalized experience?

    Register for free